Association of Chronological Age, Subjective Age, Epigenetic Age and Bio-functional Age With Serum Anti-müllerian Hormone
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Assessing the chronological age
Study Overview
Brief Summary
This study aims to assess the association between aging and serum anti-müllerian hormone.
Detailed Description
As life expectancy is increasing and has significant effects on health, economy and other aspects, the need for an Active and Healthy ageing (AHA) strategy becomes more important. Although ageing is often defined by chronological age (CA), it is significantly influenced by other factors such as psychological, social and mental-emotional factors. To evaluate these influences, the bio-functional status (BFS) was created which consists of 45 non-invasive assessments of different categories and reflects a normal middle-European population. By means of BFS the bio-functional age (BFA) can be calculated, revealing individual strengths and resources for healthy ageing as well as potential health risks.
In women ageing leads to a depletion of the ovarian reserves and change of sex hormone levels introducing menopause. Age at menopause is associated with several health issues. Women with premature (age ≤40) or early menopause (age ≤45) are not only considered to have higher risk for osteoporosis but also cardiovascular diseases and cognitive disorders such as dementia. Late menopause (age ≥55) increases the risk of breast and ovarian cancer. Timely preventative measures might limit these risks. For example, hormone replacement therapy has shown to reduce later development of issues associated with premature or early menopause.
The difficulty lies in the variability of age at menopause between 40 and 60 years. In order to take appropriate preventative measures, the age of menopause has to be predicted individually for every woman. This requires a reliable predictive marker for menopause. In studies serum anti-müllerian hormone (AMH) was described as a potential predictor.
AMH is synthetized in granulosa cells of the follicles and reduces the effects of the follicle-stimulating hormone (FSH) on said cells preventing further recruitment of follicles. Hence, AMH is associated with the functional ovarian reserve and declines with age. It is mainly used for detection of reproductive age in women and might be a reliable predictive marker for menopause.
Using the epiAge-test the epigenetic age, also called the biological age, can be calculated. The epiAge-Test was created by Prof. Dr. Moshe Szyf based on the research of Steve Horvath's epigenetic clock. Horvath discovered that DNA methylation can be directly associated with ageing. The methylation occurs on cytosine nucleotides followed by guanine nucleotides creating so called CpG-islands. Taking mathematical and statistical analyses into account, Horvath identified 353 CpG-islands which were consistently altered with age. Szyf further developed Horvath's calculator and created the epiAge-test using 13 CpG-islands that show the highest correlation with ageing to calculate the epigenetic age.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Ages
- 35 Years to 45 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Informed consent as documented by signature
- •Age between 35 and 45 years
- •German as native language
- •Regular menstrual cycle with a mean length of 21-35 days
- •Next menstrual period is predictable within a 7-day time frame
- •Willing to attend bio-functional status analysis and to give blood and saliva samples
Exclusion Criteria
- •Pregnancy or breastfeeding
- •Hormonal contraception
- •Chronic diseases
- •Mental illness
- •Smoking >10 cigarettes per day or over 10 packyears
- •Consumption of >30g alcohol per day (>1 liter of beer or >0.3 liter of wine)
- •Inability to give consent
Outcomes
Primary Outcomes
Assessing the chronological age
Time Frame: At baseline, once per participant
Evaluated by birthdate of participant
Secondary Outcomes
- Serum anti-müllerian hormone (AMH)(At baseline, once per participant)
- Serum follicle-stimulating hormone (FSH)(At baseline, once per participant)
- Serum estradiol (E2)(At baseline, once per participant)
- Subjective age(At baseline, once per participant)
- Externally estimated age(At baseline, once per participant)
- Bio-functional age (BFA)(At baseline, once per participant)
- Epigenetic age(At baseline, once per participant)
